Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Who It's For (Based on Trial Inclusion Criteria) BMI 30 (obesity) OR BMI 27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, sleep apnea) Adults ages 1875 (some trials include narrower age ranges) People who have tried lifestyle interventions (diet and exercise) without sufficient weight loss Those with type 2 diabetes seeking both glucose control and weight loss People with obesity-related conditions that would improve with major weight reduction Who Should Avoid Retatrutide Based on trial exclusion criteria and the drug's mechanism, retatrutide is likely not appropriate for: Pregnancy or breastfeeding: Not studied in these populations
Most people pick Sunday evening or Monday morning to start the week
2015;32(10):e29-30
A comprehensive evaluation of these supplements within evidence-based frameworks is essential to guide their safe and effective integration into clinical practice
To learn more about this report, Within the global anti-obesity drug market segmented by drug class, GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists hold the highest share with an estimated 23.1% in 2026, driven largely by their dual role in appetite regulation and glucose metabolism
